Celgene Hikes Outlook: But What About the Receptos Dilution?

Business is good at Celgene (CELG), or so it seems from today’s second-quarter financial results. But investors are wondering how the biotech giant managed to boost full-year earnings forecasts in light of the dilution to per share profits expected from the acquisition of Receptos (RCPT) announced earlier this month. Mark Schoenebaum, an analyst at Evercore [...]